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Aims: The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were
assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Methods: This post-hoc pooled analysis evaluated patients receiving 10 mg exenatide BID for
12–30 weeks or 2 mg exenatide QW for 24–30 weeks in exenatide clinical development
program trials. Race was self-identified.
Results: A total of 4625 patients were included (exenatide BID: Asian, n = 787; White, n = 2223;
exenatide QW: Asian, n = 511; White, n = 1104). At study end, glycated hemoglobin (HbA1c),
fasting glucose (FG), body weight, post-prandial glucose (PPG), and PPG excursions were
significantly reduced (all P < 0.0001 vs baseline). For exenatide BID, HbA1c reduction was greater
in Asians (P < 0.0001 vs Whites), whereas HbA1c reduction did not differ by race for exenatide
QW. FG reduction did not differ by race for either exenatide formulation. Weight reduction was
significantly greater in Whites (P < 0.0001 vs Asians), regardless of exenatide formulation. PPG
reduction was greater in Asians (P < 0.0001 vs Whites) for exenatide BID but did not differ by race
for exenatide QW. For exenatide BID, reductions in PPG excursions for all meals were signifi-
cantly greater in Asians (P < 0.0001 vs Whites), whereas only post-breakfast and post-lunch
excursions were significantly greater in Asians for exenatide QW (P = 0.0009 and P = 0.0189 vs
Whites, respectively). Common adverse events included nausea, headache, and diarrhea.
Conclusions: Exenatide BID and QW improved glycemic control, including PPG, in Asian and
White patients with T2DM. With exenatide BID, Asian patients exhibited significantly
greater reductions in HbA1c and PPG than White patients. Both exenatide formulations
were well tolerated in both groups.
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In Western countries, type 2 diabetes mellitus (T2DM) is
typically associated with obesity and advanced age [1]. In
Asian countries, however, T2DM often occurs in patients with
a lower body mass index (BMI) and in young and middle-aged
adults [1]. Asian individuals often have higher levels of
abdominal adiposity and lower muscle mass than their White
counterparts, meaning a BMI in the ‘‘normal’’ range in the
West (<25 kg/m2) may be associated with a higher risk in Asian
patients [1]. It has also been suggested that the development of
T2DM in Asian patients is associated with impaired early-
phase insulin secretion [2].
The characteristics of T2DM differ between Asian and
White patients. Although both post-prandial glucose (PPG) and
fasting glucose (FG) levels are important contributors to excess
hyperglycemia, PPG levels are thought to be more influential in
Asian patients, whereas FG levels appear more important in
White patients [3]. The Asian diet comprises foods with high
glycemic loads, such as rice and refined wheat [1]; however,
excessive PPG excursions among Asian patients appear to be
more than a function of diet. In response to identical meals,
Asian patients exhibit greater PPG excursions than White
patients [4]. Furthermore, the pattern of diabetes complica-
tions seen in Asian patients is different compared with White
patients. For example, Asians are more prone to end-stage
renal disease [1].
Exenatide, a glucagon-like peptide-1 (GLP-1) receptor
agonist, has multiple glucoregulatory effects including
suppression of elevated post-prandial glucagon secretion,
enhanced glucose-dependent insulin secretion, and slow-
ing of gastric emptying [5]. Two formulations of exenatide
are approved in the United States, European Union, Japan,
China, and other countries for the treatment of adult
patients with T2DM. The twice-daily (BID) formulation is
given before the two major meals of the day. There is also
an extended-release, once-weekly (QW) formulation, in
which the active molecule is dispersed into biodegradable
microspheres to allow extended diffusion following injec-
tion [6]. Exenatide BID and QW have been extensively
evaluated in controlled clinical trials in multiple countries
and races, including White and Asian patients. However,
there is more limited information to inform if clinical
practice should differ between ethnic groups. The current
post-hoc analysis assessed the efficacy and safety of
exenatide BID and exenatide QW in populations of Asian
and White patients with T2DM who participated in selected
studies from the exenatide clinical development program.
These studies provided the majority of data leading to the
regulatory approval of exenatide BID and exenatide QW for
clinical use.
2. Patients, materials, and methods
2.1. Study and patient selection
This retrospective analysis employed pooled individual
patient-level data derived from selected studies within theexenatide global integrated database. This database contains
all exenatide BID and exenatide QW clinical studies compris-
ing the exenatide clinical development program. Databases
such as these are commonly required in order to respond
effectively to analysis requests from regulatory authorities.
For the purposes of the current analysis, clinical studies
employing exenatide BID and exenatide QW were selected
based on the following criteria:
I. Randomized and controlled.
II. 12 to 30 weeks for exenatide BID; 24 to 30 weeks for
exenatide QW.
III. Primary objective was the safety and efficacy of exenatide
BID or exenatide QW versus placebo or comparator in
patients with T2DM already receiving treatment with diet
and exercise with or without oral concomitant glucose-
lowering therapy.
IV. Outcomes comprised glycated hemoglobin (HbA1c) level,
FG, body weight, blood pressure, heart rate, lipid profile,
immunogenicity, and safety data including hypoglycemia.
Pre-prandial glucose and PPG excursions from self-moni-
tored blood glucose (SMBG) assessments were evaluated
when available.
V. Designed to maintain stable background glucose-lowering
therapies. Studies that permitted reductions in back-
ground sulfonylurea (SFU) use due to hypoglycemia were
included, but studies with continuous reductions in SFU
doses were excluded. Studies using basal insulin as a
background therapy were also excluded.
Any disputes regarding inclusion of studies were resolved
through discussion by the authors until consensus was
reached.
This retrospective pooled analysis included intention-to-
treat (ITT) patients treated with either 10 mg exenatide BID
(5 mg for 4 weeks and 10 mg thereafter) or 2 mg exenatide QW.
Patients self-identified as a single race; Asian and White
patients were selected for this analysis.
All studies included were conducted in accordance with the
Declaration of Helsinki (1964), including the current Seoul
revision (2008; when applicable), and were consistent with
Good Clinical Practice and applicable laws and regulations. All
patients provided written informed consent for the original
clinical trials.
2.2. Statistical analysis
Changes from baseline at study end within each group for
HbA1c, FG, body weight, blood pressure, heart rate, lipid
parameters (ITT population), and SMBG responses (SMBG
population; see below for definition) were assessed for
statistical significance using paired student t-tests with
missing data imputed using the last observation carried
forward (LOCF) method. The proportion of patients with
various anti-exenatide antibody titers (0, 25, 125, 625, 3125, and
15,625) at baseline and study end was also assessed in the ITT
population.
Differences in HbA1c, FG, body weight, and SMBG responses
between Asian and White patients were evaluated for exena-
tide BID and exenatide QW separately using independent
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exenatide BID and exenatide QW were not tested directly.
Because not all studies included SMBG assessments,
which were necessary to determine PPG, a subset of pooled
patient data from studies that employed SMBG assessments
evaluated SMBG responses. These SMBG measurements,
which were collected by patients and entered into a diary,
were used to plot 6-point curves to enable a visual
representation of the daily blood glucose profile and to
calculate 2 h glucose excursions for breakfast, lunch, and
dinner (the average difference in blood glucose measured
before and 2 h after each meal). Safety data were analyzed
descriptively for the ITT population. Adverse events (AEs)
with a frequency of 5% in any race subpopulation were
reported. The frequency of hypoglycemia (blood glucose
<3.00 mmol/L), stratified according to SFU use, was also
reported. All analyses were performed using SAS, version 9.2
(SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Included studies
3.1.1. Exenatide BID-treated patients
Of 69 exenatide BID studies from the clinical development
program, 21 randomized active comparator- or placebo-
controlled, efficacy and safety studies met the inclusion
criteria for analysis (Supplementary Fig. S1). Results of
individual studies were previously reported [7–27]. The ITT
population consisted of 787 Asian patients, the majority of
whom were from China (27.8%), Japan (23.6%), India (22.6%),
Korea (11.0%), Taiwan (9.3%), the United States (3.2%), and
Europe (0.9%); and 2223 White patients, the majority of whom
were from Europe (62%) and the United States (29.9%). The
SMBG population comprised 728 Asian and 1714 White
patients.
At baseline, in the ITT and SMBG populations, Asian
patients had significantly lower body weight, higher HbA1c,
and lower FG (all P < 0.0001 Asians vs Whites), and numeri-
cally lower BMI compared with White patients. Additionally,
SFUs were used in a numerically higher percentage of Asian
compared with White patients in both the ITT and SMBG
populations (Table 1).
3.1.2. Exenatide QW-treated patients
Of 20 exenatide QW studies from the clinical development
program, eight randomized, comparator-controlled, efficacy
and safety studies met the inclusion criteria for analysis
(Supplementary Fig. S2). Individual study results were previ-
ously reported [22,25,28–33]. The ITT population consisted of
511 Asian patients, the majority of whom were from India
(29.4%), China (20.4%), Korea (16.8%), Japan (15.3%), Taiwan
(12.9%), the United States (1.6%), and Europe (1.6%); and 1104
White patients, the majority of whom were from Europe
(55.2%) and the United States (26.1%). The SMBG population
comprised 450 Asian and 634 White patients.
Consistent with the exenatide BID analysis, at baseline,
Asian patients in the ITT and SMBG populations receiving
exenatide QW had significantly lower body weight, higherHbA1c, lower FG (all P < 0.0001 Asians vs Whites), and
numerically lower BMI and higher use of SFU compared with
White patients (Table 1).
3.2. HbA1c and FG
3.2.1. Exenatide BID-treated patients
Exenatide BID-treated Asian and White patients showed
significant decreases in HbA1c and FG from baseline to
study end (P < 0.0001 for change from baseline). A signifi-
cantly greater mean decrease in HbA1c in Asian (1.08%;
95% confidence interval [CI]: 1.16, 1.00 [11.8 mmol/mol;
95% CI:12.7, 10.9]) than in White patients (0.85%; 95%
CI: 0.89, 0.80 [9.3 mmol/mol; 95% CI:9.7, 8.7])
occurred (P < 0.0001 Asians vs Whites; Fig. 1A). However,
the mean decrease in FG was comparable in Asian
(1.17 mmol/L; 95% CI: 1.38, 0.96) and White patients
(1.11 mmol/L; 95% CI: 1.23, 0.99) (P = 0.6025 Asians vs
Whites; Fig. 1B).
3.2.2. Exenatide QW-treated patients
HbA1c and FG in exenatide QW-treated Asian and White
patients decreased significantly from baseline to study end
(P < 0.0001 change from baseline). Exenatide QW produced
similar mean decreases in HbA1c in Asian and White patients
(1.43%; 95% CI: 1.53, 1.33 [15.6 mmol/mol; 95% CI:16.7,
14.5] and 1.37%; 95% CI: 1.43, 1.31 [15.0 mmol/mol; 95%
CI:15.6, 14.3], respectively) (P = 0.3117 Asians vs Whites:
Fig. 1A). Exenatide QW produced similar mean decreases in FG
in Asian (1.94 mmol/L; 95% CI: 2.17, 1.70) and White
patients (2.04 mmol/L; 95% CI: 2.21, 1.88) (P = 0.4665
Asians vs Whites; Fig. 1B).
3.3. PPG (SMBG subgroup)
3.3.1. Exenatide BID-treated patients
Fig. 2A shows the SMBG profile at baseline and study end
for Asian and White patients receiving exenatide BID
(SMBG population). Daily mean baseline pre-prandial
blood glucose (across all meals) and daily mean baseline
PPG (across all meals) were significantly higher in Asian
(9.48 mmol/L and 12.87 mmol/L, respectively) compared
with White patients (9.01 mmol/L and 10.91 mmol/L)
(both P < 0.0001 Asians vs Whites). The magnitude of
PPG excursions at baseline were significantly greater
among Asian than White patients, irrespective of meal
(breakfast, lunch, or dinner) (all P < 0.0001 Asians vs
Whites; Table 2).
At study end, daily mean pre-prandial blood glucose was
8.09 mmol/L in Asian and 7.80 mmol/L in White patients,
corresponding to similar mean changes from baseline of 1.40
and 1.26 mmol/L, respectively (both P < 0.0001 vs baseline).
At study end, daily mean PPG was 9.07 mmol/L in Asian and
8.39 mmol/L in White patients, corresponding to mean
changes from baseline of 3.77 and 2.56 mmol/L, respec-
tively (both P < 0.0001 vs baseline). Reductions in PPG
excursions from baseline to end of treatment were significant
in both populations, irrespective of meal (all P < 0.0001 vs
baseline; Table 2), and were significantly greater in Asians (all
P < 0.0001 vs Whites; Table 2).
Table 1 – Baseline and demographic characteristics of the ITT and SMBG populations for exenatide BID and exenatide QW.
Parameter Exenatide BID Exenatide QW
ITT population SMBG population ITT population SMBG population
Asian
(n = 787)
White
(n = 2223)
Asian
(n = 728)
White
(n = 1714)
Asian
(n = 511)
White
(n = 1104)
Asian
(n = 450)
White
(n = 634)
Age, mean (SD), y 55.4 (10.1) 57.2 (9.7) 55.5 (10.0) 57.5 (9.5) 53.3 (10.7) 56.9 (9.7) 53.4 (10.9) 57.1 (9.7)
Men, n (%) 428 (54.4) 1288 (57.9) 392 (53.8) 974 (56.8) 277 (54.2) 630 (57.1) 245 (54.4) 359 (56.6)
Body weight, mean (SD), kg 70.8 (12.7)* 95.2 (18.2) 70.4 (11.8) 94.0 (17.8) 70.9 (12.9)* 95.7 (18.6) 70.5 (12.7) 96.1 (17.9)
BMI, mean (SD), kg/m2 26.7 (3.7) 32.9 (4.8) 26.7 (3.4) 32.7 (4.6) 26.8 (3.7) 33.3 (5.3) 26.8 (3.7) 33.3 (5.1)
Waist circumference, mean (SD), cm 92.6 (10.7) 111.0 (12.7) 92.6 (10.3) 111.0 (12.7) 92.8 (10.5) 110.1 (13.3) 92.9 (10.6) 109.8 (12.6)
HbA1c, mean (SD), % 8.4 (1.0)* 8.1 (1.0) 8.5 (1.0) 8.0 (0.9) 8.7 (1.1)* 8.3 (1.0) 8.7 (1.1) 8.3 (1.0)
HbA1c, mean (SD), mmol/mol 68 (11)* 65 (11) 69 (11) 64 (10) 72 (12)* 67 (11) 72 (12) 67 (11)
Fasting glucose, mean (SD), mmol/L 9.2 (2.5)* 9.7 (2.5) 9.2 (2.5) 9.7 (2.5) 9.2 (2.5)* 9.7 (2.5) 9.1 (2.5) 9.7 (2.6)
Duration of diabetes, mean (SD), y 8.5 (6.0) 7.1 (5.5) 8.5 (6.0) 7.2 (5.5) 7.0 (5.3) 6.9 (5.7) 6.9 (5.2) 6.3 (5.7)
Systolic BP, mean (SD), mmHg 130.1 (14.5) 133.5 (15.4) 129.9 (14.5) 134.9 (15.8) 129.8 (14.8) 132.2 (14.4) 130.0 (15.0) 132.2 (15.2)
Diastolic BP, mean (SD), mmHg 79.2 (9.0) 79.8 (9.1) 79.1 (9.0) 80.4 (9.3) 79.1 (8.8) 79.2 (9.0) 79.1 (8.8) 79.6 (9.3)
Total cholesterol, mean (SD), mmol/L 4.8 (1.0) 4.9 (1.1) 4.8 (1.0) 4.8 (1.1) 4.6 (1.0) 4.6 (1.2) 4.6 (1.0) 4.7 (1.2)
HDL-C, mean (SD), mmol/L 1.3 (0.3) 1.2 (0.3) 1.3 (0.3) 1.2 (0.3) 1.2 (0.3) 1.1 (0.3) 1.2 (0.3) 1.1 (0.3)
LDL-C, mean (SD), mmol/L 2.7 (0.9) 2.8 (0.9) 2.7 (0.9) 2.7 (0.9) 2.6 (0.8) 2.6 (1.0) 2.6 (0.8) 2.6 (1.0)
Triglycerides, mean (SD), mmol/L 1.8 (1.5) 2.2 (1.7) 1.7 (1.3) 2.1 (1.6) 1.9 (1.3) 2.2 (1.7) 1.9 (1.4) 2.2 (1.5)
Background glucose-lowering
therapy, n (%)
Metformin alone 154 (19.6) 987 (44.4) 149 (20.5) 833 (48.6) 124 (24.3) 415 (37.6) 114 (25.3) 267 (42.1)
Sulfonylurea alone 44 (5.6) 121 (5.4) 38 (5.2) 35 (2.0) 32 (6.3) 23 (2.1) 31 (6.9) 6 (0.9)
Metformin + sulfonylurea 476 (60.5) 753 (33.9) 442 (60.7) 578 (33.7) 253 (49.5) 412 (37.3) 211 (46.9) 160 (25.2)
BID: twice daily; BMI: body mass index; BP: blood pressure; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; ITT: intent-to-treat; LDL-C: low-density lipoprotein cholesterol;
QW: once daily; SD: standard deviation; SMBG: self-monitored blood glucose.
* P < 0.0001 vs White (no other baseline statistical comparisons were undertaken for the variables presented in this table).
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Fig. 2B shows the SMBG profile at baseline and study end for
Asian and White patients receiving exenatide QW (SMBG
population). Daily mean baseline pre-prandial blood glucose
was 9.61 mmol/L in both Asian and White patients. As in the
exenatide BID population, daily mean baseline PPG values
were significantly higher in Asian than in White patients (13.16
and 11.81 mmol/L, respectively; P < 0.0001 Asians vs Whites).
The magnitude of PPG excursions at baseline were signifi-
cantly greater in Asian compared with White patients,
irrespective of meal (all P < 0.0001 Asians vs Whites; Table 2).
At study end, mean study pre-prandial blood glucose was
7.51 mmol/L in Asian and 7.28 mmol/L in White patients,
corresponding to similar mean changes from baseline of 2.15
and 2.36 mmol/L, respectively (both P < 0.0001 vs baseline).Fig. 1 – Mean changes from baseline in: (A) HbA1c; (B) FG; and (C
(ITT population). For exenatide BID, baseline mean (SD) HbA1c 
and mean (95% CI) change from baseline HbA1c values in mmol/
S8.7). For exenatide QW, baseline mean (SD) HbA1c values in m
(95% CI) change from baseline HbA1c values in mmol/mol were:
BID: twice daily; BL: baseline; CI: confidence interval; FG: fasting
QW: once weekly; SD: standard deviation. *For exenatide BID, P
were <0.0001, <0.0001, and <0.0001 for HbA1c, FG, and body wei
White differences in baseline values were <0.0001, <0.0001, anAt study end, mean PPG was 10.00 mmol/L in Asian and
8.86 mmol/L in White patients, corresponding to similar mean
changes from baseline of 3.22 and 3.02 mmol/L, respec-
tively (both P < 0.0001 vs baseline). Reductions in PPG
excursions from baseline to end of treatment were significant
in both populations, irrespective of meal (all P < 0.003 vs
baseline; Table 2), and were significantly greater in Asians for
post-breakfast and post-lunch glucose excursions only
(P = 0.0009 and P = 0.0189 vs Whites, respectively).
3.4. Body weight
3.4.1. Exenatide BID-treated patients
Mean change in body weight was 1.79 kg (95% CI: 1.98, 1.60;
P < 0.0001 vs baseline) in Asian and 2.88 kg (95% CI: 3.06,-1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0
Mean change in HbA1c and 95% CI (%)
-2.5 -2.0 -1.5 -1.0 -0.5 0.0
Mean change in FG and 95% CI (mmol/L)
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0
Mean change in body weight and 95% CI (kg)
) body weight in patients receiving exenatide BID and QW
values in mmol/mol were: Asian = 68 (11), White = 65 (11);
mol were: Asian = S11.8 (S12.7, S10.9), White = S9.3 (S9.7,
mol/mol were: Asian = 72 (12), White = 67 (11); and mean
 Asian = S15.6 (S16.7, S14.5), White = S15.0 (S15.6, S14.3).
 glucose; HbA1c: glycated hemoglobin; ITT: intent-to-treat;
-values for Asian vs White differences in baseline values
ght, respectively. yFor exenatide QW, P-values for Asian vs
d <0.0001 for HbA1c, FG, and body weight, respectively.
Table 2 – Effect of exenatide BID and QW on post-meal BG excursions (SMBG population), and on blood pressure, heart
rate, and lipid profile (ITT population).
Exenatide BID Exenatide QW
Asian White Asian White
Patients in the SMG population 728 1714 450 634
Post-breakfast 2 h BG excursion (mmol/L)
Baseline
n 721 1633 447 617
Mean (SD) 3.89 (2.74) 2.20 (2.40) 3.91 (2.80) 2.47 (2.44)
P-value Asian vs White <0.0001 <0.0001
Change from baseline
n 626 1378 418 510
Mean (SD) 3.22 (3.36) 1.92 (2.72) 1.47 (2.91) 0.86 (2.62)
95% CI (3.48, 2.95) (2.07, 1.78) (1.75, 1.19) (1.09, 0.63)
P-value vs baseline <0.0001 <0.0001 <0.0001 <0.0001
P-value Asian vs White <0.0001 0.0009
Post-lunch 2 h BG excursion (mmol/L)
Baseline
n 719 1629 447 610
Mean (SD) 3.27 (2.77) 1.68 (2.30) 3.47 (3.03) 1.92 (2.31)
P-value Asian vs White <0.0001 <0.0001
Change from baseline
n 621 1380 417 504
Mean (SD) 1.40 (3.38) 0.38 (3.47) 0.81 (3.24) 0.35 (2.63)
95% CI (1.67, 1.14) (0.57, 0.20) (1.12, 0.49) (0.58, 0.12)
P-value vs baseline <0.0001 <0.0001 <0.0001 0.0029
P-value Asian vs White <0.0001 0.0189
Post-dinner 2 h BG excursion (mmol/L)
Baseline
n 718 1629 448 613
Mean (SD) 3.03 (2.70) 1.82 (2.46) 3.26 (3.02) 2.22 (2.52)
P-value Asian vs White <0.0001 <0.0001
Change from baseline
n 621 1381 417 505
Mean (SD) 2.60 (3.86) 1.57 (3.15) 0.93 (3.10) 0.73 (2.86)
95% CI (2.90, 2.29) (1.74, 1.41) (1.23, 0.63) (0.98 0.48)
P-value vs baseline <0.0001 <0.0001 <0.0001 <0.0001
P-value Asian vs White <0.0001 0.3091
Patients in the ITT population 787 2223 511 1104
Diastolic blood pressure (mmHg)*
Baseline
n 787 2223 511 1104
Mean (SD) 79.2 (8.96) 79.8 (9.07) 79.1 (8.75) 79.2 (9.03)
Change from baseline
n 755 2114 507 1101
Mean (SD) 1.4 (9.12) 1.2 (9.21) 1.1 (9.12) 0.6 (8.94)
95% CI (2.02, 0.71) (1.60, 0.81) (1.93, 0.34) (1.12, 0.06)
P-value vs baseline <0.0001 <0.0001 0.0052 0.0283
Systolic blood pressure (mmHg)*
Baseline
n 787 2223 511 1104
Mean (SD) 130.1 (14.50) 133.5 (15.39) 129.8 (14.80) 132.2 (14.13)
Change from baseline
n 755 2114 507 1101
Mean (SD) 3.3 (15.28) 2.8 (15.19) 4.3 (15.10) 3.0 (13.69)
95% CI (4.43, 2.25) (3.47, 2.17) (5.63, 2.99) (3.83, 2.21)
P-value vs baseline <0.0001 <0.0001 <0.0001 <0.0001
Heart rate (bpm)*
Baseline
n 678 2223 511 1104
Mean (SD) 76.99 (9.21) 74.39 (9.75) 76.56 (9.39) 74.06 (9.44)
Change from baseline
n 673 2204 507 1101
Mean (SD) 0.14 (9.41) 0.48 (9.97) 1.36 (9.78) 1.55 (9.89)
95% CI (0.85, 0.58) (0.07, 0.90) (0.50, 2.21) (0.97, 2.14)
P-value vs baseline 0.7094 0.0233 0.0019 <0.001
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Table 2 (Continued )
Exenatide BID Exenatide QW
Asian White Asian White
Total cholesterol (mmol/L)*
Baseline
n 550 2183 506 1067
Mean (SD) 4.79 (1.01) 4.86 (1.11) 4.61 (0.99) 4.63 (1.16)
Change from baseline
n 524 1995 498 1045
Mean (SD) 0.16 (0.92) 0.08 (0.83) 0.13 (0.79) 0.15 (0.85)
95% CI (0.24, 0.08) (0.12 0.05) (0.20, 0.06) (0.21, 0.10)
P-value vs baseline 0.0001 <0.0001 0.0003 <0.0001
Calculated non-HDL cholesterol (mmol/L)*
Baseline
n 550 2178 506 1067
Mean (SD) 3.52 (1.01) 3.68 (1.09) 3.39 (0.96) 3.50 (1.12)
Change from baseline
n 525 1190 498 1045
Mean (SD) 0.12 (0.89) 0.10 (0.80) 0.13 (0.76) 0.17 (0.82)
95% CI (0.20, 0.04) (0.14, 0.07) (0.20, 0.07) (0.22, 0.12)
P-value vs baseline 0.002 <0.0001 <0.0001 <0.0001
HDL cholesterol (mmol/L)*
Baseline
n 550 2182 506 1067
Mean (SD) 1.28 (0.31) 1.18 (0.30) 1.22 (0.32) 1.12 (0.31)
Change from baseline
n 525 1996 498 1045
Mean (SD) 0.04 (0.18) 0.02 (0.18) 0.01 (0.17) 0.01 (0.18)
95% CI (0.05, 0.02) (0.01, 0.03) (0.01, 0.02) (0.00, 0.02)
P-value vs baseline <0.0001 <0.0001 0.4702 0.0127
LDL cholesterol (mmol/L)*
Baseline
n 550 2143 506 1067
Mean (SD) 2.75 (0.87) 2.76 (0.92) 2.59 (0.84) 2.56 (0.97)
Change from baseline
n 523 1919 498 1045
Mean (SD) 0.11 (0.67) 0.04 (0.66) 0.09 (0.69) 0.10 (0.68)
95% CI (0.17, 0.06) (0.07, 0.01) (0.15, 0.03) (0.14, 0.06)
P-value vs baseline <0.0001 0.0160 0.0037 <0.0001
Triglycerides (mmol/L)*
Baseline
n 550 2183 507 1082
Mean (SD) 1.79 (1.52) 2.25 (1.74) 1.88 (1.34) 2.19 (1.71)
Change from baseline
n 525 1995 499 1060
Mean (SD) 0.02 (2.06) 0.13 (1.47) 0.12 (1.12) 0.18 (1.61)
95% CI (0.19, 0.16) (0.20, 0.07) (0.21, 0.02) (0.27, 0.08)
P-value vs baseline 0.8492 <0.0001 0.0206 0.0004
Triglycerides (mmol/L)*
Baseline
n 550 2183 507 1082
Geometric mean (SE) 1.51 (0.03) 1.90 (0.02) 1.60 (0.04) 1.85 (0.03)
GMR study end to baseline
n 534 1893 499 1060
Geometric mean (SE) 1.0 (0.02) 0.9 (0.01) 1.0 (0.02) 0.9 (0.01)
Geometric 95% CI (0.938, 1.010) (0.929, 0.964) (0935, 1.008) (0.911, 0.958)
P-value vs baseline 0.1502 <0.0001 0.1264 <0.0001
BG : blood glucose; BID: twice daily; bpm: beats per minute; CI: confidence interval; GMR: geometric mean ratio; HDL: high-density lipoprotein;
ITT: intention-to-treat; LDL: low-density lipoprotein; QW: once weekly; SD: standard deviation; SE: standard error; SMBG: self-monitored blood
glucose.
* P-values for Asians vs Whites were not calculated for these variables.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 4 ( 2 0 1 6 ) 1 6 0 – 1 7 2166
02
4
6
8
10
12
14
16
A) Exenatide BID
M
ea
n
SM
B
G
SE
(m
m
ol
/L
)
Pre 2-hr Post Pr e 2-hr Post Pr e 2-hr Post
Baseline
At study end
White (n=1714)
Baseline
At study end
Asian (n=728)
Breakfast Lunch Dinner
P-values change from BL
Asian <0.0001 <0.0001 <0.0 001 <0.0001 <0.0001 <0.0001
White <0.0001 <0.0001 <0.0001 <0.0001 <0.0 001 <0.0001
P-values Asian vs Whit e
At BL 0.7880 <0.0001 <0.0001 <0.0 001 <0.0001  <0.0001
Change from BL 0.7122 <0.0001 0.1281 <0.0001 0.1900 <0.0001
0
2
4
6
8
10
12
14
16
B) Exenatide QW
M
ea
n
SM
B
G
SE
(m
m
ol
/L
)
Pre 2-hr Post Pr e 2-hr Post Pr e 2-hr Post
Baseline
At study end
White (n=634)
Baseline
At study end
Asian (n=450)
Breakfast Lunch Dinner
P-values change from BL
Asian <0.0001 <0.0001 <0.0 001 <0.0001 <0.0001 <0.0001
White <0.0001 <0.0001 <0.0 001 <0.0001 <0.0001 <0.0001
P-values Asian vs Whit e
At BL 0.0005 <0.0001 0.2729 <0.0001 0.1218 <0.0001
Change from BL 0.0001 0.8396 0.6816 0.0771 0.8261 0.4063
Fig. 2 – Summary of the 6-point SMBG profile showing mean pre-prandial and post-prandial glucose concentrations at
baseline and at study end in: (A) exenatide BID-treated patients; and (B) exenatide QW-treated patients (SMBG population).
BID: twice daily; BL: baseline; QW: once weekly; SE: standard error; SMBG: self-monitored blood glucose.
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significantly greater reduction in White patients (P < 0.0001 vs
Asians; Fig. 1C). The percentage weight reduction from baseline
was 2.5% and 3.1% in Asian and White patients, respectively.
3.4.2. Exenatide QW-treated patients
Mean change in body weight was 1.63 kg (95% CI: 1.86,
1.39; P < 0.0001) in Asian and 2.79 kg (95% CI: 3.03, 2.56;
P < 0.0001) in White patients, with a significantly greater
reduction in White patients (P < 0.0001 vs Asians; Fig. 1C). The
percentage reduction in weight from baseline was 2.3% and
2.9% in Asian and White patients, respectively.3.5. Blood pressure, heart rate, lipid profile, and
immunogenicity
3.5.1. Exenatide BID-treated patients
Blood pressure and most lipid outcomes improved signifi-
cantly from baseline in both populations (Table 2). In response
to exenatide BID treatment, both diastolic blood pressure
(DBP) and systolic blood pressure (SBP) decreased significantly
from baseline: 1.4 and 3.3 mmHg in Asian and 1.2 and
2.8 mmHg in White patients, respectively (all P < 0.001 vs
baseline). Mean change from baseline in heart rate in Asian
and White patients was 0.14 beats per minute (bpm;
Table 3 – Frequent adverse events (I5% of overall population) and hypoglycemia in patients receiving exenatide BID and
exenatide QW (ITT population).
Exenatide BID Exenatide QW
Asian (n = 787) White (n = 2223) Asian (n = 511) White (n = 1104)
Frequent adverse events
Nausea 211 (26.8) 807 (36.3) 65 (12.7) 207 (18.8)
Diarrhea 53 (6.7) 257 (11.6) 55 (10.8) 125 (11.3)
Nasopharyngitis 61 (7.8) 268 (12.1) 30 (5.9) 109 (9.9)
Injection site nodule NR NR 35 (6.8) 99 (9.0)
Headache 25 (3.2) 185 (8.3) 16 (3.1) 108 (9.8)
Vomiting 108 (13.7) 281 (12.6) 42 (8.2) 75 (6.8)
Decreased appetite 77 (9.8) 92 (4.1) NR NR
Constipation 46 (5.8) 85 (3.8) 32 (6.3) 67 (6.1)
Injection site induration NR NR 39 (7.6) 8 (0.7)
Injection site pruritus NR NR 30 (5.9) 56 (5.1)
Hypoglycemia
With SFU 243/594 (40.9) 416/930 (44.7) 86/309 (27.8) 130/450 (28.9)
Without SFU 23/193 (11.9) 230/1293 (17.8) 15/202 (7.4) 63/654 (9.6)
Frequent adverse events are reported as n (%) and hypoglycemia as n/N (%). NR: No adverse events (5% of overall population) were recorded
with this term. BID: twice daily; ITT: intent-to-treat; QW: once weekly; SFU: sulfonylurea.
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respectively (Table 2).
The magnitude of change across lipid outcomes was
similar in Asian and White populations; small changes of
unclear clinical relevance in high-density lipoprotein choles-
terol (HDL-C) were observed in both groups. At study end,
triglycerides were not significantly reduced (0.02 mmol/L;
95% CI: 0.19, 0.16; P = 0.8492 vs baseline) in Asian patients and
were significantly reduced in White patients (0.13 mmol/L;
95% CI: 0.20, 0.07; P < 0.0001 vs baseline). The geometric
mean ratio of study end to baseline triglycerides was not
significantly different from unity in the Asian population (1.0;
P = 0.1502 vs baseline) but was significantly decreased in the
White population (0.9; P < 0.0001 vs baseline).
After treatment with exenatide BID, the number of patients
with anti-exenatide antibodies was 238/716 (33%) in Asian
patients compared with 759/1597 (48%) in White patients. Of
patients who were antibody-positive at study end, the
majority in both groups exhibited low (125) antibody titers:
217/238 (91%) Asian and 661/759 (87%) White patients. In the
overall populations, high titers (625) at study end were
observed in 21/716 (3%) Asian and 98/1597 (6%) White patients.
3.5.2. Exenatide QW-treated patients
Blood pressure and most lipid outcomes improved signifi-
cantly from baseline in both populations (Table 2). DBP
decreased significantly in Asian (1.1 mmHg; P = 0.0052 vs
baseline) and White patients (0.6 mmHg; P = 0.0283 vs
baseline) treated with exenatide QW, as did SBP (4.3 and
3.0 mmHg, respectively; both P < 0.0001 vs baseline). Mean
changes in heart rate from baseline at study end in Asian and
White patients were 1.36 bpm (P = 0.0019 vs baseline) and
1.55 bpm (P < 0.001 vs baseline), respectively (Table 2).
The magnitude of change across lipid outcomes was
similar in Asian and White populations; small increases of
unclear clinical relevance in HDL-C were observed in both
Asian and White patients. For triglycerides, there was a
reduction at study end of 0.12 mmol/L (95% CI: 0.21, 0.02;
P = 0.0206 vs baseline) in Asian patients and a significantreduction of 0.18 mmol/L (95% CI: 0.27, 0.08; P = 0.0004 vs
baseline) in White patients. The geometric mean ratio of study
end to baseline was not significantly different from unity in
the Asian population (1.0; P = 0.1264 vs baseline) but signifi-
cantly decreased in the White population (0.9; P < 0.0001 vs
baseline).
After treatment with exenatide QW, anti-exenatide anti-
bodies were detected in 266/449 (59%) Asian and 413/707 (58%)
White patients. Of patients who were antibody-positive at study
end, the majority in both groups exhibited low (125) antibody
titers: 215/266 (81%) Asian and 335/413 (81%) White patients.
In the overall populations, high titers (625) at study end were
seen in 51/449 (11%) Asian and 78/707 (11%) White patients.
3.6. Tolerability
Table 3 shows the most frequently reported AEs and
hypoglycemia. Nausea was the most common AE reported
by both populations treated with either formulation. Patients
treated with exenatide BID had a higher frequency of
decreased appetite. A lower frequency of nausea was reported
in Asian compared with White patients. Other common AEs
were nasopharyngitis, headache and diarrhea, which were
also reported less commonly by Asian patients than by White
patients. In Asian and White patients who received exenatide
BID or exenatide QW, hypoglycemia was three- to four-fold
more common in patients treated with SFUs than in those not
treated with SFUs.
In this analysis, 6.8% of Asian patients treated with
exenatide QW spontaneously reported injection site nodule
formation as an AE compared with 9.0% of White patients.
Injection site induration occurred more often in Asian (7.6%)
than in White patients (0.7%).
4. Discussion
International guidelines recognize that treatment of hyper-
glycemia, excess weight, hypertension and hyperlipidemia are
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ethnicity, to reduce the complications of diabetes [34]. An ideal
approach to investigating the efficacy of exenatide formula-
tions in patients of different races or ethnicities would be to
prospectively compare these therapies in a large dedicated
clinical trial with randomization stratified by race or ethnicity.
In the absence of such a trial, we retrospectively explored the
responses to exenatide in Asian and White patients using
individual patient-level data pooled from a large clinical trials
program, an approach favored over the use of aggregated trial-
level data as in conventional meta-analysis [35,36].
This paper demonstrates that treatment with exenatide
BID or exenatide QW significantly improved glycemic control,
body weight, blood pressure and lipids in Asian and White
patients, and was well tolerated in both populations. Statisti-
cally significant differences in magnitude of response to
treatment between Asian and White populations were
observed.
Patients from different genetic or cultural backgrounds
may have different pathophysiological defects in T2DM, and
this analysis supports that hypothesis. At baseline, Asian
patients had marginally lower FG but higher HbA1c, PPG and
PPG excursion values than White patients. Among Asian
patients with T2DM, PPG is a predominant contributor to
excess hyperglycemia in patients whose T2DM is generally
well controlled, and is equally important as pre-prandial
glucose in patients whose T2DM is moderately to poorly
controlled [3]. Furthermore, in the current analysis, baseline
body weight was significantly lower among Asian compared
with White patients, although this was not reflected in
baseline blood pressure. Asian patients also had lower
triglyceride values at baseline compared with the reference
White population.
Because of the differences in pathophysiological defects,
differences in the efficacy of medications may be seen among
patients with different genetic or cultural backgrounds,
particularly if the medications differentially affect the
mechanism of interest. Exenatide BID has been shown to
control PPG more effectively than exenatide QW due to the
timing and duration of administration [22]. Asian patients
likely to have a PPG defect who received exenatide BID showed
significantly greater decreases from baseline in PPG and post-
meal PPG excursions than White patients with a lesser PPG
defect. In contrast, Asian patients receiving exenatide QW
showed numerically similar decreases from baseline in PPG to
White patients, which did not significantly differ by race, and
significantly greater reductions than White patients in post-
breakfast and post-lunch glucose excursions. The differing
patterns of PPG response between these exenatide therapies
may relate to both mechanism of drug action and patient
background.
Reductions in FG following treatment with either formula-
tion were similar in Asian and White patients. In the exenatide
BID group, HbA1c change, which reflects both FG and PPG
changes, was reduced to a significantly greater extent in Asian
compared with White patients, while the magnitude of HbA1c
reductions with exenatide QW was greater than with exena-
tide BID regardless of race. The greater influence of Asian race
on HbA1c and PPG responses with exenatide BID supports
the observation that PPG may be the predominant factorinfluencing HbA1c and, consequently, diabetes in this popu-
lation. However, higher baseline HbA1c and lower baseline
BMI (as observed in the Asian population) are predictors for
greater HbA1c reductions [37,38], which may have affected
this analysis.
The findings of this study of individual patient-level data
are consistent with those from two large meta-analyses of
aggregated clinical trial data that assessed the effects of either
GLP-1 analogs or dipeptidyl peptidase-4 (DPP-4) inhibitors in
Asian compared with non-Asian patients [37,38]. Both studies
showed that Asian patients exhibited significantly larger
reductions in HbA1c, with similar reductions in FG, compared
with non-Asian patients [37,38]. PPG was only assessed in the
DPP-4 study and decreased to a greater extent in the Asian
population, although not significantly [37,38].
Exenatide treatment results in weight reduction irrespec-
tive of race or ethnicity [10–12,34,38,39]. In the current
analysis, body weight loss was smaller in Asian compared
with White patients. This may reflect the higher baseline body
weight in White patients (higher baseline BMI is associated
with greater weight loss with exenatide [40]).
Asian and White patients treated with either formulation
showed statistically significant improvement from baseline in
most lipid parameters, although the clinical relevance of these
changes is unclear at present. Asian and White patients
showed statistically significant reductions from baseline in
low-density lipoprotein cholesterol and small but statistically
significant increases in HDL-C (except for Asian patients
treated with exenatide QW). While Asian patients did not
exhibit significant changes from baseline in serum triglyceride
levels, this parameter was significantly reduced in the White
population. Lower baseline triglyceride concentrations for
Asian patients may account for this lack of statistical
significance at study end in the Asian population.
Blood pressure was significantly improved in Asian and
White patients treated with exenatide BID or QW. Although
body weight was higher among White compared with Asian
patients, this was not reflected by differences in blood
pressure. Heart rate was increased at study end (except in
Asians receiving exenatide BID), which may represent a
compensatory increase consequent to decreased blood
pressure.
Anti-exenatide antibodies were found in Asian and White
patients with similar frequencies of low- and high-titer
antibodies against exenatide QW. Frequencies were less
similar in Asian and White patients with the BID formulation,
where patients are intermittently exposed to exenatide. The
similarity in response to continuous exposure with the QW
formulation suggests little difference in immune response to
exenatide. A previous study showed that the presence of high-
titer anti-exenatide antibodies was associated with some
reduction in efficacy, particularly for exenatide QW, but with
no difference in safety except an increased likelihood of
injection site reactions [41].
Both formulations were well tolerated in Asian and White
populations. The AEs experienced by patients were typical for
exenatide BID and QW. AEs such as headache, nasophar-
yngitis and nausea were reported more frequently in White
than in Asian patients in both exenatide BID and exenatide
QW populations. This disparity in reporting frequency may be
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between Asian and White patients [42]. A higher frequency of
hypoglycemia when exenatide is administered concomitantly
with SFUs has been previously reported in a Phase III study
including Asian and White patients [32]. This was reflected in
the current analysis, where the frequency of hypoglycemia
was higher with concomitant SFU use, regardless of exenatide
formulation or race. However, a lower proportion of Asian
patients reported hypoglycemia than White patients, despite
Asian patients having a lower body weight, lower FG levels,
and more frequent concomitant SFU use.
Although we did not assess statistical differences between
the exenatide formulations, a number of observations can be
noted. Our results provide further support that exenatide BID is
associated with greater PPG control and exenatide QW with
greater FG control, as expected based on the delivery and
pharmacokinetics of exenatide QW treatment [6]. Drucker et al.
[22] demonstrated that PPG excursions and absolute reduction
in PPG excursions were greater with exenatide BID than with
exenatide QW. The same authors also showed greater efficacy
of exenatide QW in reducing FG levels compared with
exenatide BID, suggesting that continued drug exposure with
exenatide QW results in greater fasting glucagon suppression
[22]. Gastrointestinal AEs were reported with lower frequency
with exenatide QW than with exenatide BID, which may also
be explained by the extended diffusion of the active drug from
the biodegradable microspheres following exenatide QW
injection [6]. Hypoglycemia was more common with exenatide
BID than with the long-acting QW formulation, regardless of
background SFU; again, this may be related to pharmacokinetic
differences between the two formulations.
This study has limitations. This was a retrospective, post-
hoc analysis of pooled data from studies performed by the
company seeking regulatory approvals of exenatide formula-
tions. Some studies only recruited specific races from specific
regions meaning that outcomes between Asian and White
patients were not directly compared within the same study.
Unidentified confounders may have contributed to apparent
differences. The SMBG data were essential to review the
effects of exenatide treatment on PPG; however, SMBG data
were only available in a subset of the overall patient
population and compliance rates for diary entry of SMBG
values were not available. Since all studies were performed by
company alliances and integrated analyses were anticipated
for regulatory purposes, similar laboratory testing and
glucose-monitoring procedures were followed; however,
potential variation in these procedures may have occurred.
Due to self-reporting of AEs and self-identification of race (no
verification was carried out with genetic markers), potential
inaccuracies could have occurred. In addition, because
patients identified a single race, mixed-race patients were
not detected. Furthermore, heterogeneity across different
ethnic and cultural subgroups as well as socioeconomic
conditions were not considered. Selected exenatide BID
studies included those with a minimum treatment duration
of 12 weeks, whereas for exenatide QW, the minimum
duration was 24 weeks. Because of the immediate onset of
drug action with exenatide BID, a minimum study duration of
12 weeks was considered sufficient for HbA1c changes to be
detected [43]. With exenatide QW, however, steady-state drugconcentration is not reached until 6 to 8 weeks after initiation,
thus longer times on therapy were considered necessary to
achieve detectable reductions in HbA1c [44].
To conclude, in this pooled analysis among Asian and
White patients, both exenatide formulations effectively
improved indices of glycemic control, including HbA1c, FG,
and PPG excursions, and were well tolerated with low
frequencies of hypoglycemia (in the absence of SFUs). At
baseline, specific characteristics observed in the Asian
population versus the reference White population included
greater PPG responses, lesser body weight, and more frequent
concomitant SFU use. Upon treatment with exenatide BID or
QW, the Asian population appeared to have significantly
greater HbA1c reduction (BID only), greater PPG reduction (BID
only), smaller weight loss and fewer reports of nausea.
Alongside data from randomized, controlled, global clinical
trials in mixed populations, this post-hoc analysis supports
the conclusion that exenatide BID or QW is an appropriate
treatment option when Asian patients with T2DM are
considered suitable for injectable therapy (including those
patients who are failing oral glucose-lowering drugs). Longer-
term, real-world observations and assessments may deter-
mine if multiple benefits from use of exenatide—including
HbA1c, PPG, weight and blood pressure reduction, and
improvements in lipid profile—translate into reduction of
diabetes complications for Asian patients. Furthermore, long-
term global clinical studies such as the ongoing EXSCEL trial
will provide further information on the effect of exenatide
treatment on cardiovascular outcomes in both Asian and
White patients.
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